Prospective pilot study with [⁸⁹Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE).

ABSTRACT:

Purpose of the report

Metastatic triple negative breast cancer (mTNBC) is aggressive with drug-resistance. Evaluating new markers is an unmet need. Anhydrase carbonic-IX (CA-IX), a hypoxia-mediated breast tumor growth regulator, is important for maintaining BC stem cells within a hypoxic region. This pilot prospective study "OPALESCENCE" assessed [⁸⁹Zr]Zr-DFO-89Zr-girentuximab (TLX250-CDx) positron emission tomography/computed tomography (PET/CT), in comparison with [¹⁸F]F-fluoro-deoxy-glucose (FDG) PET/CT in mTNBC patients (NCT04758780).

Materials and methods

Patients underwent FDG and TLX250-CDx PET/CT and conventional imaging (CI) if needed. Intravenous administration of 37±10% MBq TLX250-CDx was performed, The PET/CT was acquired at Day 3 or 5 post

SUBMITTER: Rousseau C 

PROVIDER: S-EPMC12920357 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature